SCHEMBL5539504

SCHEMBL5539504

O=C1[N]CCN1Cc1cccc(Cl)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.60
CYP2C9 P11712 1/20 0.60
CYP2C19 P33261 1/20 0.60
SIGMAR1 Q99720 1/20 0.51
P2RX7 Q99572 1/20 0.49
DRD2 P14416 1/20 0.49
DRD3 P35462 1/20 0.49
KCNH2 Q12809 1/20 0.49
ALDH1A1 P00352 2/20 0.47
HPGD P15428 2/20 0.47
TDP1 Q9NUW8 1/20 0.47
KDM4E B2RXH2 2/20 0.46
KMT2A Q03164 4/20 0.45
ATM Q13315 1/20 0.45
CLPP Q16740 1/20 0.44
ADORA3 P0DMS8 1/20 0.44
MAOB P27338 1/20 0.44
ADORA2A P29274 1/20 0.44
MEN1 O00255 2/20 0.44
EGLN1 Q9GZT9 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5535754 0.84 L3MBTL1 (0.42) MAPTCYP2C9CYP2C19P2RX7DRD2
SCHEMBL5251526 0.84 DDB1 (0.49) CYP2C9CYP2C19SIGMAR1DRD3KCNH2
SCHEMBL5543146 0.82 ERCC1 (0.46) SIGMAR1P2RX7DRD3KCNH2ALDH1A1
SCHEMBL5537145 0.82 SMN1; SMN2 (0.50) HPGDTDP1KDM4EKMT2ACLPP
SCHEMBL9704692 0.82 BCL2L1 (0.40) MAPTCYP2C9CYP2C19SIGMAR1DRD2
SCHEMBL5548109 0.82 ALDH1A1 (0.50) ALDH1A1KMT2ACLPPMEN1CYP11B1
SCHEMBL5537759 0.80 POLB (0.49) MAPTSIGMAR1DRD3KCNH2ALDH1A1
SCHEMBL5545709 0.78 CMA1 (0.56) MAPTSIGMAR1ALDH1A1KDM4EKMT2A
SCHEMBL5547283 0.77 ALDH1A1 (0.49) SIGMAR1ALDH1A1CLPP
SCHEMBL5546659 0.76 CHRNB2 (0.34) MAPTCYP2C9CYP2C19P2RX7DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MAPT 4117/4885CYP2C9 2351/4885CYP2C19 2521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.